Biology Reference
In-Depth Information
[29] Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and
final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carbopl-
atin
/
paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol
29; 2866-74.
Search WWH ::
Custom Search